期刊文献+

马蹄金素酯类衍生物的合成及表征 被引量:4

Synthesis and Characterization of Matijing-Su Ester Derivatives
原文传递
导出
摘要 以L-酪氨酸为起始原料,在碱性条件下与苯甲酰氯缩合得到N-苯甲酰基-O-苯甲酰基-L-酪氨酸(Ⅰ),收率87%;然后,在氯甲酸异丁酯-N-甲基吗啉(IBCF-NMM)的作用下与L-苯丙氨醇缩合形成具有双酰胺结构的N-(N-苯甲酰基-O-苯甲酰基-L-酪氨酰基)-L-苯丙氨醇(Ⅱ),收率80.7%;经碱水解得N-(N-苯甲酰基-L-酪氨酰基)-L-苯丙氨醇(Ⅲ),收率84.5%;在N,N-二甲基甲酰胺和无水K2CO3的作用下与二甲氨基氯乙烷盐酸盐反应4 h后得N-(N-苯甲酰基-O-二甲氨基乙基-L-酪氨酰基)-L-苯丙氨醇(Ⅳ),收率79%;最后,化合物Ⅳ在以1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(EDC.HCl)和4-二甲氨基吡啶(DMAP)为缩合剂的条件下与有机酸反应,合成了以苯丙二肽类化合物马蹄金素〔N-(N-苯甲酰基-L-苯丙氨酰基)-O-乙酰基-L-苯丙氨醇,MTS〕为先导化合物的衍生物共11个,其结构经NMR、ESI-MS进行了确认。 N-Benzoyl-O-benzoyl-L-tyrosine ( Ⅰ ) was synthesized in 87 % yield by reaction of L-tyrosine with benzoyl chloride under alkaline condition. N-(N-Benzoyl-O-benzoyl-L-tyrosyl)-L-phenylalaninol (Ⅱ) was formed by condensation with L-phenylalaninol under the isobutyl chloroformate / 4- methylmorpholine (IBCF-NMM) in 80.7% yield ; N- (N-benzoyl-L-tyrosyl) -L-phenylalaninol ( Ⅲ ) was synthesized by alkaline hydrolysis of N-( N-benzoyl-O-benzoyl-L-tyrosyl)-L-phenylalaninol (Ⅱ) in 84.5% yield. The reaction of Ⅲ with 2-dimethylaminoethyl chloride hydrochloride in the presence of K2CO3 gave N-[ N-benzoyl-O-( 2-dimethylaminoethyl )-L-tyrosyl ]-L-phenylalaninol ( Ⅳ ) in 79% yield. 11 compounds of derivatives of MTS were synthesized by esterification of compounding N- [ N- benzoyl-O- (2-dimethylaminoethyl) -L-tyrosyl ] -L-phenylalaninol ( Ⅳ ) with a series of organic acids in the presence of EDC · HC1 and 4-dimethylamino pyridine. Their structures were confirmed by NMR and ESI-MS.
出处 《精细化工》 EI CAS CSCD 北大核心 2013年第8期925-931,943,共8页 Fine Chemicals
基金 国家"重大新药创制"科技重大专项资助项目(2011ZX09102-009-2) 贵州省中药现代化资助项目([2010]5018 [2012]5054) 贵阳中医学院研究生教育创新计划项目(ZYYCX12018)~~
关键词 马蹄金素 衍生物 双酰胺 酯化反应 医药原料 Matijing-Su derivatives bisamides esterification drug materials
  • 相关文献

参考文献3

  • 1梁光义,刘玉明,徐必学.苯丙氨醇类化合物作为制备治疗乙肝药品的应用及其制备方法[P].CN:02160309.x,2003-08-27.
  • 2邱净英,黄正明,潘卫东,曹佩雪,梁光义.马蹄金素衍生物的合成及抗乙肝病毒活性[J].中国药科大学学报,2012,43(5):390-394. 被引量:16
  • 3梁光义,徐必学,刘昌孝,等.N-(N-苯甲酰基-苯丙氨酰基)-苯丙氨酸二肽衍生物及其制备方法和用途[P].CN:200610201016.4.2007-03-28.

二级参考文献16

  • 1Pang R,Tao JY,Zhang SL,ef al. In vitro antiviral activity of lute-in against hepatitis B virus [ J]. Phyiother Res,2010,24 (11):1627-1 630.
  • 2Lin KW,Kirchner JT. Information from your family doctor:hepati-tis B infection [ J ]. Am Farn Physician ,2004,69 (1) :86.
  • 3Park N,Song I,Chung Y. Chronic hepatitis B in hepatocarcino-genesis[ J] ? Postgrad Med 7,2006,82(970) :507 -515.
  • 4Karayiannis P. Current therapies for chronic hepatitis B virus in-fection[ J]. Expert Rev Anti Infect 77ier,2004,2(5) :745 -760.
  • 5Fattovich G,Brollo L,Giustina G,et al. Natural-history and prog-nostic factors for chronic hepatitis type B[ J]. Gul,1991,32(3);294 -298.
  • 6Lavanchy D. Hepatitis B virus epidemiology, disease burden,treatment,and current and emerging prevention and control meas-ures[ J]. J Viral Hepat,2Q04,11(2) :97 - 107.
  • 7Mast EE,Alter MJ,Margolis HS. Strategies to prevent and controlhepatitis B and C virus infections : a global perspective [ J ].Vaccirie,1999,17(13/14) :1 730 -1 733.
  • 8Shaw T, Bartholomeusz A, Locamini S. HBV drug resistance:mechanisms,detection and interpretation[ J]. J Hepatol,2006,44(3):593 -606.
  • 9Yang WJ,Sun KG,Liu CR,ef al. Analysis report of anti-hepatitisB virus drug[ J]. 中国现代药物应用[J]. 2009,3( 19):87 -88.
  • 10Colomio RT, Rose RE, Pokomowski K,et al. Four year assess-ment of ETV resistance in nucleoside-naive and lamivudinerefractory patients[ J]. J Hepatol,2007,46( SI ) :294.

共引文献15

同被引文献31

  • 1陈志卫,胡永洲,吴好好,蒋惠娣.黄酮类化合物的合成及其血管舒张作用[J].药学学报,2005,40(11):1001-1007. 被引量:14
  • 2邓艳君,石静波,姜力勋,高静,姚其正.嘧啶并呋咱核苷衍生物的制备及其活性初探[J].化学学报,2006,64(18):1911-1915. 被引量:10
  • 3车庆明,潘丽怡,陈颖,何红.灯盏花乙素苷元的药动学研究[J].中国药学杂志,2007,42(18):1418-1421. 被引量:39
  • 4XU B X,HUANG Z M,LIANG G Y,et al.Synthesis and anti-hepatitis B virus activities of Matijing-Su derivatives[J].Bioorg Med Chem,2009,17(8):3118-3125.
  • 5Qiu J Y,Xu B X,Huang Z M,et al.Synthesis and biological evaluation of Matijing-Su derivatives as potent anti-HBV agents[J].Bioorganic & Medicinal Chemistry,2011,19:5352-5360.
  • 6HU Z X,AN Q,LI K F,et al.Identification,synthesis,and strategy for minimization of potential impurities in the preclinical anti-HBV drug Y101[J].Organic Process Research & Development,2013,17(9):1156-1167.
  • 7Kennedy M. , Alexopoulos S. P. , Curr. Opin. Organ. Tran. , 20111, 15(3): 310-315.
  • 8Maria L. C. , Ver6nica L. M. , Jos6 R. O. , Alejandro S. , Pharm. Res. , 2010, 27, 1184-1202.
  • 9Sebastien D. , Jan B. , Anita R. M. , J. Org. Chem. , 2011, 76( 1 ): 105-126.
  • 10Hyunah C. , Youhoon C. , Yongseok C. , Judy M. , Raymond F. S. , Chung K. C. , J. Med. Chem. , 2003, 46(3) , 389-398.

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部